JOINN Laboratories (China) Co., Ltd. (Stock Code: 6127) Revises Annual Caps for 2024 Property Service Agreements

Bulletin Express

Oct 31, 2025

JOINN Laboratories (China) Co., Ltd. (Stock Code: 6127) has announced the revision of annual caps related to property management arrangements with Beijing Joinn Biologics. The 2024 Property Service Agreements initially covered the period from 1 September 2024 to 31 December 2026, with past transaction amounts fully exempt from certain connected transaction requirements. However, due to increased demand for electricity and heating and a need to accommodate business growth, the transaction will no longer qualify as fully exempt.

Revised annual caps have been set at RMB6 million for the financial year ending 31 December 2025 and RMB6.5 million for 2026. Historical figures show a transaction amount of RMB0.88 million in 2024 and RMB2.24 million for the nine months ended 30 September 2025. With the highest applicable percentage ratios now exceeding 0.1% but remaining below 5%, the revision triggers reporting, announcement, and annual review obligations under the Listing Rules without requiring a circular or independent shareholders’ approval.

Beijing Joinn Biologics is considered a connected person of the listed entity, as it is held 91.07% by Joinn Biologics (HK) and 8.93% by the Company, with controlling shareholders Ms. Feng and Mr. Zhou holding indirect interests. The Board of JOINN Laboratories (China) Co., Ltd. approved the revised annual caps, citing alignment with normal commercial terms and the Group’s operational needs.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1183288872"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183288872\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183288872?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 01:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183288872","market":"hk","top_or_hot":-1,"title":"JOINN Laboratories (China) Co., Ltd. (Stock Code: 6127) Revises Annual Caps for 2024 Property Service Agreements","media":"Bulletin Express","content":"<p>JOINN Laboratories (China) Co., Ltd. (Stock Code: 6127) has announced the revision of annual caps related to property management arrangements with Beijing Joinn Biologics. The 2024 Property Service Agreements initially covered the period from 1 September 2024 to 31 December 2026, with past transaction amounts fully exempt from certain connected transaction requirements. However, due to increased demand for electricity and heating and a need to accommodate business growth, the transaction will no longer qualify as fully exempt.</p>\n<p>Revised annual caps have been set at RMB6 million for the financial year ending 31 December 2025 and RMB6.5 million for 2026. Historical figures show a transaction amount of RMB0.88 million in 2024 and RMB2.24 million for the nine months ended 30 September 2025. With the highest applicable percentage ratios now exceeding 0.1% but remaining below 5%, the revision triggers reporting, announcement, and annual review obligations under the Listing Rules without requiring a circular or independent shareholders’ approval.</p>\n<p>Beijing Joinn Biologics is considered a connected person of the listed entity, as it is held 91.07% by Joinn Biologics (HK) and 8.93% by the Company, with controlling shareholders Ms. Feng and Mr. Zhou holding indirect interests. The Board of JOINN Laboratories (China) Co., Ltd. approved the revised annual caps, citing alignment with normal commercial terms and the Group’s operational needs.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JOINN Laboratories (China) Co., Ltd. (Stock Code: 6127) Revises Annual Caps for 2024 Property Service Agreements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJOINN Laboratories (China) Co., Ltd. (Stock Code: 6127) Revises Annual Caps for 2024 Property Service Agreements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-31 01:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JOINN Laboratories (China) Co., Ltd. (Stock Code: 6127) has announced the revision of annual caps related to property management arrangements with Beijing Joinn Biologics. The 2024 Property Service Agreements initially covered the period from 1 September 2024 to 31 December 2026, with past transaction amounts fully exempt from certain connected transaction requirements. However, due to increased demand for electricity and heating and a need to accommodate business growth, the transaction will no longer qualify as fully exempt.</p>\n<p>Revised annual caps have been set at RMB6 million for the financial year ending 31 December 2025 and RMB6.5 million for 2026. Historical figures show a transaction amount of RMB0.88 million in 2024 and RMB2.24 million for the nine months ended 30 September 2025. With the highest applicable percentage ratios now exceeding 0.1% but remaining below 5%, the revision triggers reporting, announcement, and annual review obligations under the Listing Rules without requiring a circular or independent shareholders’ approval.</p>\n<p>Beijing Joinn Biologics is considered a connected person of the listed entity, as it is held 91.07% by Joinn Biologics (HK) and 8.93% by the Company, with controlling shareholders Ms. Feng and Mr. Zhou holding indirect interests. The Board of JOINN Laboratories (China) Co., Ltd. approved the revised annual caps, citing alignment with normal commercial terms and the Group’s operational needs.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06127","symbol_name":"昭衍新药","start_time":0,"source_url":"","article_id":"1183288872","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183288872","pubTimestamp":1761844891,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"JOINN Laboratories (China) Co., Ltd. (Stock Code: 6127) has announced the revision of annual caps related to property management arrangements with Beijing Joinn Biologics. The 2024 Property Service...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06127":"昭衍新药"},"translate_title":"中诚医药（中国）有限公司（股份代号：6127）修订2024年物业服务协议的年度上限","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06127":1},"content_text":"JOINN Laboratories (China) Co., Ltd. (Stock Code: 6127) has announced the revision of annual caps related to property management arrangements with Beijing Joinn Biologics. The 2024 Property Service Agreements initially covered the period from 1 September 2024 to 31 December 2026, with past transaction amounts fully exempt from certain connected transaction requirements. However, due to increased demand for electricity and heating and a need to accommodate business growth, the transaction will no longer qualify as fully exempt.\nRevised annual caps have been set at RMB6 million for the financial year ending 31 December 2025 and RMB6.5 million for 2026. Historical figures show a transaction amount of RMB0.88 million in 2024 and RMB2.24 million for the nine months ended 30 September 2025. With the highest applicable percentage ratios now exceeding 0.1% but remaining below 5%, the revision triggers reporting, announcement, and annual review obligations under the Listing Rules without requiring a circular or independent shareholders’ approval.\nBeijing Joinn Biologics is considered a connected person of the listed entity, as it is held 91.07% by Joinn Biologics (HK) and 8.93% by the Company, with controlling shareholders Ms. Feng and Mr. Zhou holding indirect interests. The Board of JOINN Laboratories (China) Co., Ltd. approved the revised annual caps, citing alignment with normal commercial terms and the Group’s operational needs.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}